Substance Dependence Clinical Trial
Official title:
Characterizing Alpha5 Nicotinic Receptors in Alcohol and Nicotine Dependence
Purpose: This is an outpatient, randomized, double-blinded, placebo-controlled study in which either varenicline (twice daily) or placebo will be administered over a 12 week study period to examine genetic influences on treatment response to varenicline for reduction of hazardous drinking.
Hazardous alcohol use and alcohol use disorders (AUDs) are an area of large unmet medical
needs. Although there has been some progress with pharmacotherapy for alcohol-dependent
individuals, a critical need for the development of novel and additional therapeutic
approaches remains. Pharmacotherapy development for AUDs as a therapeutic area has had
several recent advancements, where clinically as well as commercially successful additions
to available treatment options are available and several more are expected in the near
future. Based on recent preclinical work, we believe that varenicline has potential to
become one of the first among those newly evolving treatments.
In this study, participants with nicotine dependence will receive standard varenicline or
placebo treatment over the recommended course of 12 weeks. Since our research question
addresses whether alcohol drinking also diminishes with varenicline treatment, we will not
ask participants to alter alcohol use; we will simply follow their use over time. Study
visits will take place at the Ernest Gallo Clinic and Research Center. The procedures to be
completed include vital signs, blood samples at screening and end of study, urine toxicology
screening and the completion of standard questionnaires. No special facilities are required
for these procedures. Group therapy (which is not a research procedure, but part of standard
nicotine dependence treatment) will take place at the Gallo Center.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00887367 -
EtOH Interaction Study
|
Phase 1 | |
Completed |
NCT01036061 -
GSK618334 Repeat Dose Study
|
Phase 1 | |
Completed |
NCT01189799 -
Motivational Therapy for Substance Users With Depression
|
N/A | |
Completed |
NCT01381133 -
Adolescent Outpatient and Continuing Care Study
|
Phase 3 | |
Recruiting |
NCT04430257 -
Pre-exposure Prophylaxis (PrEP) for Health
|
N/A | |
Completed |
NCT01128140 -
Efficacy Trial of Warrior Check-Up
|
Phase 2 | |
Completed |
NCT03767907 -
Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial
|
N/A | |
Recruiting |
NCT05833399 -
Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
|
||
Withdrawn |
NCT01515917 -
Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)
|
N/A | |
Completed |
NCT00208143 -
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
|
Phase 4 | |
Withdrawn |
NCT03762798 -
Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone
|
N/A | |
Completed |
NCT03048552 -
Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3
|
N/A | |
Active, not recruiting |
NCT04768920 -
Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD)
|
N/A | |
Recruiting |
NCT05410561 -
Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients
|
N/A | |
Recruiting |
NCT05679284 -
A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
|
||
Withdrawn |
NCT00908206 -
Effects of GSK598809 on Brain Activation in Abstinent Alcoholics
|
Phase 1 | |
Recruiting |
NCT05348317 -
Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders
|
N/A | |
Recruiting |
NCT01741415 -
Distress Tolerance Treatment for Substance Users
|
Phase 2 | |
Active, not recruiting |
NCT01621711 -
Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care
|
N/A | |
Active, not recruiting |
NCT00609089 -
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
|
Phase 1/Phase 2 |